Share
1,366 Posts.
lightbulb Created with Sketch. 570
clock Created with Sketch. 10/03/25
10:59
Share
Originally posted by Eagle0:
↑
It's possible they may be looking at licensing different jurisdictions for 2591 ie North America, Europe and Asia keeping in mind they don't want split the indications, but what becomes of Neuren after that? A holding company with no more tricks up its sleeve, or it develops trofinetide for other indications when 2591 is the superior of the two drugs? I think Gerry's answer was a broad one and meant to entail takeovers also. Surely the company is more valuable being sold in its entirety given the royalties and milestone payments from trofinetide is significant.
Expand
That is how I interpreted it - I don't think his response was restricted to licensing, it was a broader comment on any/all commercial activity.
(20min delay)